The MarketBeat Podcast -Getting Tactical With Rob Isbitts



In this episode of the MarketBeat podcast, Kate talks to Rob Isbitts of Sungarden Investment. Rob has been an asset manager, analyst and now a financial publisher.

You can listen wherever you get your podcasts including:

Apple Podcasts – Spotify – iHeart – Overcast – Amazon

In this episode, Kate and Rob discuss:

Should you be concerned about investment bubbles?

How should you respond to the threat of growing inflation?

How should individual investors change their approach, given how major indexes have performed?

Why it’s important to understand tactical portfolio management and know how to implement it.

What should investors or traders do at the end of a bull market cycle?

How to think about your portfolio the same way you’d approach a fantasy football team.

How should stock investors incorporate bonds into their portfolios, given how the Federal Reserve has backstopped many areas of the fixed-income market?

How can you use bond ETFs and inverse ETFs as tactical weapons to generate returns and mitigate risk?

What’s the new income investment? How do you get yield in today’s investing environment?

A sector whose chart Rob likes right now, and why.

You can find Rob here: Sungarden Investment 

Sign up today for free MarketBeat Analyst Recommendations, sent to your inbox daily.

Apple Podcasts – Spotify – iHeart – Overcast – Amazon

7 Great Biotech Stocks to Buy in Expectations of Better Days Ahead

The biotechnology (biotech) sector was one of the best performing sectors in 2020. Many companies saw their stock prices rise as the race was on for a Covid-19 vaccine.

However, many of these companies were pre-revenue companies. Or they were companies that only had one or two in-market products or therapies. And as the calendar turned to 2021, investors took notice. And what went up quickly went down. And in the case of the biotech sector, it came down hard.

One way to tell is to look at biotech ETFs. One of the most popular ETFs, the VanEck Vectors Biotech ETF (NYSEARCA:BBH) is down more than 15%. So you can imagine what it’s been like for many individual biotech stocks. If you’re a buy-and-hold investor, you’re licking some wounds right about now.

But investors who knew what companies to buy have done well. And many of those names will continue to lead the biotech sector in 2022. In this special presentation, we give investors seven biotech stocks that represent different aspects of this diverse sector. We’re confident there’s something for investors of all risk tolerances.

View the “7 Great Biotech Stocks to Buy in Expectations of Better Days Ahead”.



Source link


Copyright © 2022 Billionaire Club Co LLC. All rights reserved

Chat
Loading the chat ...